Detailed Information on Publication Record
2021
A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A Subjects
BLANCHETTE, V. S., L. ZUNINO, V. GRASSMANN, C. BARNES, M. D. CARCAO et. al.Basic information
Original name
A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A Subjects
Authors
BLANCHETTE, V. S. (guarantor), L. ZUNINO, V. GRASSMANN, C. BARNES, M. D. CARCAO, J. CURTIN, S. JACKSON, L. KHOO, Vladimir KOMRSKA (203 Czech Republic), D. LILLICRAP, M. MORFINI, Gabriela ROMANOVÁ (203 Czech Republic, belonging to the institution), D. STEPHENS, Ester ZAPOTOCKA (203 Czech Republic), M. L. RAND and Jan BLATNÝ (203 Czech Republic, belonging to the institution)
Edition
THROMBOSIS AND HAEMOSTASIS, STUTTGART, GEORG THIEME VERLAG KG, 2021, 0340-6245
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30205 Hematology
Country of publisher
Germany
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 6.681
RIV identification code
RIV/00216224:14110/21:00121731
Organization unit
Faculty of Medicine
UT WoS
000640018700001
Keywords in English
factor VIII; hemophilia A; pharmacokinetic; observational study; population PK
Tags
International impact, Reviewed
Změněno: 25/2/2022 10:56, Mgr. Tereza Miškechová
Abstract
V originále
Standard pharmacokinetic (PK) assessments are demanding for persons with hemophilia A, requiring a 72-hour washout and 5 to 11 timed blood samples. A no-washout, single-clinic visit, sparse sampling population PK (PPK) protocol is an attractive alternative. Here, we compared PK parameters obtained with a traditional washout, 6-sampling time point PPK protocol with a no-washout, single-clinic visit, reverse 2-sampling time point PPK protocol in persons with severe hemophilia A (SHA) receiving ADVATE. A total of 39 inhibitor-negative males with SHA (factor VIII activity [FVIII:C]<2%) were enrolled in a prospective sequential design PK study. Participants completed a washout, 6-sampling time point PPK protocol as well as a no-washout, reverse 2-sampling time point protocol, with samples taken during a single 3-hour clinic visit 24hours post home infusion of FVIII and then 3hours post infusion in clinic. FVIII:C levels were analyzed by one-stage and chromogenic assays; blood group and von Willebrand factor antigen (VWF:Ag) were determined; and PK parameters were analyzed using the ADVATE myPKFiT dosing tool. There was moderate to almost perfect agreement for the PK parameters obtained with the 2- and the 6- point PPK protocols using a one-stage FVIII:C assay and a substantial to almost perfect agreement using a chromogenic FVIII:C assay. Significant associations between specific PK parameters and blood group and VWF:Ag were observed. The no-washout, single-clinic visit, reverse 2-sampling time point PPK protocol can be used in the routine clinical setting since it demonstrates sufficient accuracy compared with the more demanding and less practical washout, 6-sampling time point PPK protocol in persons with SHA receiving ADVATE.